This Pot Stock Could Go Bankrupt in 2020

Green Organic Dutchman Holdings Ltd (TSX:TGOD) is the highest risk/reward stock in the industry. Should you be buying?

Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The pot industry is in turmoil. After setting dizzying new heights in 2018, the market experienced a painful bear market in 2019. Most companies experienced share price declines of at least 50%. Some stocks sank by more than 80%. That was the case with Green Organic Dutchman Holdings (TSX:TGOD).

Once a multi-billion-dollar company, Green Organic was set to revolutionize the industry with high-margin organic produce. One of its largest competitors, Aurora Cannabis, even purchased shares of Green Organic, committing to buy a significant chunk of its marijuana crop.

Then the house came falling down. Today, the stock trades at $180 million valuation, one of the smallest market caps in the industry. Few investors are paying attention to this company. Most Wall Street bankers ignore Green Organic completely.

Some think the firm is ultimately headed for bankruptcy, but it’s far from certain what will happen in 2020. If a few events go its way, Green Organic could stage an unlikely comeback. Risk-tolerant investors could double or triple their capital by betting now, when there’s blood in the streets.

Is Green Organic a bankruptcy candidate or a once-in-a-lifetime buying opportunity? Let’s find out.

A difficult history

Green Organic went public on May 2, 2018. The IPO raised more than $115 million, which, at the time, set an industry record. The company immediately began constructing massive grow operations, targeting 100% organic production, which management argued had higher margins and better differentiation.

In early 2019, Green Organic attracted the attention of industry heavyweights. Aurora purchased a 17% stake in Green Organic, with options to eventually take a controlling stake. Aurora also acquired the right to purchase 20% of Green Organic’s annual organic cannabis production. Over time, the deal ultimately would allow Aurora to purchase more than 30% of the output.

With all the excitement, Green Organic stock surpassed $8 per share, assigning it a multi-billion-dollar valuation. The good days didn’t last long. In 2019, Aurora pulled out of the agreement, selling its stake and terminating its commitment to buy Green Organic cannabis. Towards the end of the year, industry pricing began to collapse.

This brings us to the current situation.

Green Organic has massive grow facilities coming online right as pot pricing takes a nosedive. Without a committed partner, it’s no guarantee that the company can convert most of its production into actual sales dollars. Without a capital partner, Green Organic could face difficulties raising fresh cash just as it needs it most. And with massive volumes of organic output hitting the market, the pricing premium over conventional production could erode completely.

Here’s the bet

Sounds pretty terrible, right? That’s what the vast majority of investors have decided. Few people are willing to take a risk on the stock now, which is exactly why a buying opportunity exists.

TGOD stock now trades at 1.1 times 2021 revenue. The average cannabis stock trades at 2.5 times 2021 revenue. Green Organic shares could double in price and still trade at a discount to the market.

Granted, TGOD stock trades at a discount for a reason. Unlike its competitors, it hasn’t shown an ability to sell output at scale. Additionally, it needs to find fresh capital to continue its production ramp.

These factors are major questions marks, but at some point, the discount become compelling enough to take a risk. If you want exposure to major upside, there are few better buying opportunities than TGOD stock in 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »